v3.26.1
SEGMENT INFORMATION (Tables)
6 Months Ended
Jun. 30, 2026
SEGMENT INFORMATION  
Schedule of segment revenue and significant segment expenses

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Rare Neurological Diseases Segment

​

Three Months Ended June 30, 

​

Six Months Ended June 30, 

​

2026

​

2025

​

2026

​

2025

Net product revenue

$

261,280

​

$

200,489

​

$

476,667

​

$

385,222

Less:

​

​

​

​

​

​

​

​

​

​

​

Cost of product sold (a)

​

63,191

​

​

38,147

​

​

107,696

​

​

70,134

Research and development (b)

​

44,034

​

​

33,046

​

​

79,052

​

​

65,284

Sales and marketing (c)

​

32,311

​

​

28,421

​

​

62,210

​

​

56,388

General and administrative (d)

​

16,884

​

​

20,334

​

​

37,282

​

​

38,212

Depreciation and amortization

​

5,968

​

​

5,967

​

​

11,936

​

​

11,935

Stock-based compensation

​

9,576

​

​

11,394

​

​

19,884

​

​

23,844

Interest expense

​

3,070

​

​

3,646

​

​

6,304

​

​

7,482

Interest income

​

(7,072)

​

​

(5,296)

​

​

(12,829)

​

​

(10,340)

Income tax expense

​

17,834

​

​

9,861

​

​

25,033

​

​

21,478

Other segment items (e)

 

53

​

 

15,193

​

 

32,180

​

 

15,469

Consolidated net income

$

75,431

​

$

39,776

​

$

107,919

​

$

85,336

(a)Cost of product sold excluding depreciation.
(b)Research and development excluding stock-based compensation and IPR&D.
(c)Sales and marketing excluding stock-based compensation.
(d)General and administrative excluding stock-based compensation and amortization.
(e)Other segment items include other expense, net and IPR&D charges.